B+L initiates Phase III program for glaucoma drug candidate licensed from Nicox

Article

Bausch + Lomb has started its Phase III clinical program of latanoprostene bunod licensed by Nicox S.A. to B+L. B+L’s drug candidate is meant to reduce IOP in patients with elevated IOP due to glaucoma or ocular hypertension.

Sophia Antipolis, France and Madison, NJ-Bausch + Lomb (B+L) has initiated its Phase III clinical program of latanoprostene bunod (previously known as BOL-303259-X and NCX 116) licensed by Nicox S.A. to B+L.

B+L’s drug candidate is intended for the reduction of intraocular pressure (IOP) in patients with elevated IOP due to glaucoma or ocular hypertension. Latanoprostene bunod is a nitric oxide-donating prostaglandin F2-alpha analog.

This pivotal Phase III program includes two separate randomized, multicenter, double-masked, parallel-group clinical studies, APOLLO and LUNAR, designed to compare the efficacy and safety of latanoprostene bunod administered QD with timolol maleate 0.5% administered BID in lowering IOP in patients with open-angle glaucoma or ocular hypertension.

The primary endpoint of both studies, which will include a combined total of approximately 800 patients, is the reduction in mean IOP measured at specified time points during three months of treatment. The Phase III studies are pivotal for U.S. registration and will be conducted in North America and Europe.

Additional information about the studies can be found at www.clinicaltrials.gov.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
© 2025 MJH Life Sciences

All rights reserved.